The paper of Niazi in this issue of GaBI Journal argues that the FDA could make several adjustments to its guidance in order to facilitate the development of biosimilars . The Author points out that the current requirements have led to high costs and long development times which discourage small and medium-sized enterprises from entering biosimilar development. Indeed, FDA Commissioner Scott Gottlieb has stated that the biosimilar market suffers from a lack of competition [2, 3]. Some of the proposals of the author deserve comments from a global perspective.
Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.